
Phylonix Pharmaceuticals Inc Profile last edited on: 2/22/2019
CAGE: 3HEQ2
UEI: XHTYA7C7LNW4
Business Identifier: Zebrafish drug screens, assays and disease model Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: Middlesex
Congr. District: 07
County: Middlesex
Public Profile
No record of any form of business transaction past 2016. Not Phylonix had been developing and marketing novel in vivo zebrafish based eZ-Screens, for assessing drug induced toxicity and efficacy in disease models for cancers, central nervous system, cardiovascular system, and apoptosis. The company also performed gene knock down and target identification and validation services. Custom studies and screening partnerships are also available. Advantages of zebrafish as a vertebrate model for compound screening. In contrast to other vertebrate models, zebrafish completes embryogenesis in the first 72 hours. Most of the internal organs, including the cardiovascular system, gut, liver and kidney, develop rapidly in the first 24-48 hours. Zebrafish embryos are completely transparent, facilitating observation and analysis. All the precursor tissues of the brain, eyes, heart and musculature can be easily visualized using light microscopy. An important advantage of this animal model is that the morphological and molecular basis of tissue and organ development is, in general, either identical or similar to other vertebrates, including humans. Since single embryos can be maintained in fluid volumes as small as 100 µl for the first five to six days of development, they can be kept in individual microtiter wells. Reagents can then be added directly to the solution in which the embryos develop, simplifying drug dispensing and facilitating analysis. Zebrafish larva, which are permeable to small molecules, provide easy access for drug administration and vital dye staining. Small molecules, including peptides, dyes and drugs can be simply dissolved in fish water and freely diffuse into the zebrafish in the presence of carrier (e.g. 0.1% DMSO). Additional advantages include: their small size, easy maintenance and breeding, and high productivity. Use of zebrafish as an alternative animal model for drug screening can greatly accelerate the drug screening process, decrease costs, and provide more accurate results than cell-based assays
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2012 | 2 | NIH | $1,012,994 | |
Project Title: Device For Automating Zebrafish Processing | ||||
2010 | 2 | NIH | $1,261,356 | |
Project Title: Zebrafish Cytochrome P450 Assays for Assessing Drug Metabolism and Drug Safety | ||||
2010 | 1 | NIH | $191,984 | |
Project Title: Brain Cancer Xenotransplant Model For Drug Screening | ||||
2009 | 2 | NIH | $1,213,050 | |
Project Title: New Model for Eye Disease | ||||
2009 | 2 | NIH | $1,250,918 | |
Project Title: In Vivo Screen for Neuroprotective Agents |
Key People / Management
Patricia McGrath -- President
Louis J D'Amico
Maryann L Haldi
Chungi Li
Edward O'Lear -- Vice President of Finance and Business Development
Demian Park
Chuenlei Parng
Carlos E Semino
Wen L Seng
George N Serbedzija
Christopher Ton
Catherine E Willett
Louis J D'Amico
Maryann L Haldi
Chungi Li
Edward O'Lear -- Vice President of Finance and Business Development
Demian Park
Chuenlei Parng
Carlos E Semino
Wen L Seng
George N Serbedzija
Christopher Ton
Catherine E Willett